BLSM (BlossomHill Therapeutics) Debt-to-Asset : 0.14 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $16.00
View Full Analysis

What is BlossomHill Therapeutics Debt-to-Asset?

BlossomHill Therapeutics BLSM 8 Debt-to-Asset is 0.14 as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100.

BlossomHill Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.01 Mil. BlossomHill Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $22.39 Mil. BlossomHill Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was $162.97 Mil. BlossomHill Therapeutics's debt to asset for the quarter that ended in Dec. 2025 was 0.14.

BlossomHill Therapeutics  (NAS:BLSM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BlossomHill Therapeutics Debt-to-Asset Related Terms

BlossomHill Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Debt-to-Asset Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Debt-to-Asset
0.01 0.14

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Debt-to-Asset 0.01 0.14

BLSM vs : Debt-to-Asset Comparison

For the Biotechnology subindustry, BlossomHill Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BlossomHill Therapeutics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BlossomHill Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BlossomHill Therapeutics's Debt-to-Asset falls into.


BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BlossomHill Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.005 + 22.393) / 162.968
=0.14

BlossomHill Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.005 + 22.393) / 162.968
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.14 mean?
BlossomHill Therapeutics (BLSM) has a Debt-to-Asset of 0.14 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Debt-to-Asset too high?
BlossomHill Therapeutics' current Debt-to-Asset is 0.14. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Debt-to-Asset compare to ?
BlossomHill Therapeutics' Debt-to-Asset of 0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Debt-to-Asset is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Debt-to-Asset of 0.14. The current Debt-to-Asset is 0.14. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Debt-to-Asset is 0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.00
Price